Evolus reports Q2 revenue $49.3M, consensus $47.55M

David Moatazedi, Evolus’ president and CEO, said, “Revenue growth this quarter accelerated by 10 percentage points over the first quarter, reflecting accelerated momentum for Jeuveau(R) and the exceptional execution of our growth strategy by the entire Evolus team. This accelerating growth and our differentiated business model give us the confidence to raise our 2023 revenue guidance from $180 to $190 million to $185 to $195 million. As we announced in May, we are extremely excited to expand our product portfolio to include a line of five different fillers beginning in 2025, clearly leveraging our strong distribution model and loyalty programs, and accelerating our top-line growth to $700 million by 2028.”